In present study we pooled three studies and analyzed the rate of CHFR promoter hypermethylation in CRC patients, found that CHFR promoter was 8.36 times more frequently hypermethylated in CRC patients compared to normal colorectal tissue, suggesting that CHFR promoter hypermethylation is a promising biomarker for diagnosis of CRC. This evidence concerns the gene CHFR and colorectal carcinoma.